Skip to main content
Erschienen in: Medical Oncology 2/2015

01.02.2015 | Original Paper

An Anticancer Drug Unit for the whole provincial oncologic network of Piacenza: improving safety and savings

verfasst von: Patrizia Mordenti, Stefano Vecchia, Enrico Damonti, Alessandra Riva, Monica Muroni, Maria Rosa Cordani, Gabriele Cremona, Luigi Cavanna

Erschienen in: Medical Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

In recent years, the expenditure for cancer care is increased largely due to the increase in cancer prevalence, demographic changes and incorporation into clinical practice of new and expensive drugs. For these reasons, solutions to contain costs are necessaries. The drugs-related expenditure is proportionally higher in oncology than in other medical specialties and overcomes staffing costs for outpatient care. The introduction of additional measures to contain and reduce expenditures such as waste reduction and human resources optimization is highly desirable. On April 2013, we started a day-to-day monitoring of the consumption of drugs and developed an internal protocol for waste minimization, consisting of five measures. A computerized research through Medline, Cancerlit and Embase was performed, applying the words drug waste, cost-containment, Anticancer Drug Unit and stability instructions. Articles and abstracts were also identified by back-referencing from other relevant papers. Selected for the present review were papers published in English without limit of year. The day-to-day monitoring of the consumption of drugs and the internal protocol for waste minimization were able to achieve a saving of €15,700 every month. The projection of an annual cost-saving result of €188.00 corresponds to a recovery of 4 % on the spending for oncologic drugs. Our data show that in a proper structure working according to the standards of quality, safety and sterility, preserving and reusing the drug waste within the limits imposed by the datasheets, it is possible to achieve a cost-containment policy and produce durable benefits.
Literatur
1.
Zurück zum Zitat Berry SR, Bell CM, Ubel PA, Evans WK, Nadler E, Strevel EL, et al. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. J Clin Oncol. 2010;28:4149–53.PubMedCrossRef Berry SR, Bell CM, Ubel PA, Evans WK, Nadler E, Strevel EL, et al. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. J Clin Oncol. 2010;28:4149–53.PubMedCrossRef
2.
Zurück zum Zitat Khayat D. Innovative cancer therapies: putting costs into context. Cancer. 2012;118:2367–71.PubMedCrossRef Khayat D. Innovative cancer therapies: putting costs into context. Cancer. 2012;118:2367–71.PubMedCrossRef
3.
Zurück zum Zitat Hoffman JM, Shah ND, Vermeulen LC, Doloresco F, Martin PK, Blake S, et al. Projecting future drug expenditure–2009. Am J Health Syst Pharm. 2009;166:237–57.CrossRef Hoffman JM, Shah ND, Vermeulen LC, Doloresco F, Martin PK, Blake S, et al. Projecting future drug expenditure–2009. Am J Health Syst Pharm. 2009;166:237–57.CrossRef
4.
Zurück zum Zitat Bach PB. Costs of cancer care: a view from the centers for medicare and medical services. J Clin Oncol. 2007;25:187–90.PubMedCrossRef Bach PB. Costs of cancer care: a view from the centers for medicare and medical services. J Clin Oncol. 2007;25:187–90.PubMedCrossRef
5.
6.
Zurück zum Zitat Cheema PK, Gavura S, Migus M, Godman L, Yeung L, Trudeau ME. International variability in the reimbursement of cancer drugs by publically funded drug programs. Curr Oncol. 2012;19:e165–76.PubMedCentralPubMedCrossRef Cheema PK, Gavura S, Migus M, Godman L, Yeung L, Trudeau ME. International variability in the reimbursement of cancer drugs by publically funded drug programs. Curr Oncol. 2012;19:e165–76.PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Nava-Ocampo AA, Alarcón-Almanza JM, Moyao-García D, Ramírez-Mora JC, Salmerón J. Undocumented drug utilization and drug waste increase costs of pediatric anesthesia care. Fundam Clin Pharmacol. 2004;18:107–12.PubMedCrossRef Nava-Ocampo AA, Alarcón-Almanza JM, Moyao-García D, Ramírez-Mora JC, Salmerón J. Undocumented drug utilization and drug waste increase costs of pediatric anesthesia care. Fundam Clin Pharmacol. 2004;18:107–12.PubMedCrossRef
8.
Zurück zum Zitat Diehl LD, Goo ED, Sumiye L, Ferrell R. Reducing waste of intravenous solutions. Am J Hosp Pharm. 1992;49:106–8.PubMed Diehl LD, Goo ED, Sumiye L, Ferrell R. Reducing waste of intravenous solutions. Am J Hosp Pharm. 1992;49:106–8.PubMed
9.
Zurück zum Zitat Favier M, Fliche E, Bressolle F. Economic benefit of a centralized reconstitution unit of cytotoxic drugs in isolator. J Oncol Pharm Pract. 1996;2:182–5.CrossRef Favier M, Fliche E, Bressolle F. Economic benefit of a centralized reconstitution unit of cytotoxic drugs in isolator. J Oncol Pharm Pract. 1996;2:182–5.CrossRef
10.
Zurück zum Zitat Gillerman RG, Browning RA. Drug use inefficiency: a hidden source of wasted health care dollars. Anesth Analg. 2000;91:921–4.PubMedCrossRef Gillerman RG, Browning RA. Drug use inefficiency: a hidden source of wasted health care dollars. Anesth Analg. 2000;91:921–4.PubMedCrossRef
11.
Zurück zum Zitat Chaudhary K, Garg R, Bhalotra AR, Anand R, Girdhar K. Anesthetic drug wastage in the operation room: a cause concern. J Anesthesiol Clin Pharmacol. 2012;28:56–61.CrossRef Chaudhary K, Garg R, Bhalotra AR, Anand R, Girdhar K. Anesthetic drug wastage in the operation room: a cause concern. J Anesthesiol Clin Pharmacol. 2012;28:56–61.CrossRef
12.
Zurück zum Zitat AAVV, Gruppo di Lavoro in Oncologia SIFO Lombardia. Compendio farmacologico e tecnico-farmaceutico alle linee guida SIFO in Oncologia. Schede monografiche di tecnica farmaceutica. Il pensiero Scientifico Editore; 2013. p.173–257. AAVV, Gruppo di Lavoro in Oncologia SIFO Lombardia. Compendio farmacologico e tecnico-farmaceutico alle linee guida SIFO in Oncologia. Schede monografiche di tecnica farmaceutica. Il pensiero Scientifico Editore; 2013. p.173–257.
13.
Zurück zum Zitat Trissel LA. Handbook on injectable drugs. American Society of Health-System Pharmacists, Inc., 15th ed. 2009. Trissel LA. Handbook on injectable drugs. American Society of Health-System Pharmacists, Inc., 15th ed. 2009.
14.
Zurück zum Zitat Field K, Zelenko A, Kosmider S, Court K, Ng LL, Hibbert M, et al. Dose rounding of chemotherapy in colorectal cancer: an analysis of clinician attitudes and the potential impact on treatment costs. Asia Pac J Clin Oncol. 2010;6:203–9.PubMedCrossRef Field K, Zelenko A, Kosmider S, Court K, Ng LL, Hibbert M, et al. Dose rounding of chemotherapy in colorectal cancer: an analysis of clinician attitudes and the potential impact on treatment costs. Asia Pac J Clin Oncol. 2010;6:203–9.PubMedCrossRef
15.
Zurück zum Zitat Dooley MJ, Singh S, Michael M. Implications of dose rounding of chemotherapy to the nearest vial size. Support Care Cancer. 2004;12:653–6.PubMedCrossRef Dooley MJ, Singh S, Michael M. Implications of dose rounding of chemotherapy to the nearest vial size. Support Care Cancer. 2004;12:653–6.PubMedCrossRef
19.
Zurück zum Zitat Ministero del Lavoro della Salute e delle Politiche Sociali, Istituto Superiore Sanità. Norme di buona preparazione dei medicinali in farmacia. Aspetti microbiologici dei preparati. In: Farmacopea Ufficiale della repubblica Italiana, 12th edn. Libreria dello Stato; 2008. p. 1423–25. Ministero del Lavoro della Salute e delle Politiche Sociali, Istituto Superiore Sanità. Norme di buona preparazione dei medicinali in farmacia. Aspetti microbiologici dei preparati. In: Farmacopea Ufficiale della repubblica Italiana, 12th edn. Libreria dello Stato; 2008. p. 1423–25.
21.
Zurück zum Zitat Fasola G, Aprile G, Marini L, Follador A, Mansutti M, Miscoria M. Drug waste minimization as an effective strategy of cost-containment in oncology. BMC Health Serv Res. 2014;14:57.PubMedCentralPubMedCrossRef Fasola G, Aprile G, Marini L, Follador A, Mansutti M, Miscoria M. Drug waste minimization as an effective strategy of cost-containment in oncology. BMC Health Serv Res. 2014;14:57.PubMedCentralPubMedCrossRef
Metadaten
Titel
An Anticancer Drug Unit for the whole provincial oncologic network of Piacenza: improving safety and savings
verfasst von
Patrizia Mordenti
Stefano Vecchia
Enrico Damonti
Alessandra Riva
Monica Muroni
Maria Rosa Cordani
Gabriele Cremona
Luigi Cavanna
Publikationsdatum
01.02.2015
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2015
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0457-y

Weitere Artikel der Ausgabe 2/2015

Medical Oncology 2/2015 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.